Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis-Reference-Cited by-同舟云学术

Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis

Published:2015-11-18 Issue:3 Volume:27 Page:241-246
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Ohba Fuminori,Nomoto Maiko,Hojo Seiichiro,Akama Hideto

Publisher

Informa UK Limited

Subject

Dermatology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10256018808623883

Reference19 articles.

1. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report

2. Leukocyte and Lymphocyte Cyclic AMP Responses In Atopic Eczema

3. Elevated leukocyte cyclic AMP—phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP—agonist hyporesponsiveness

4. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Topical anti-inflammatory treatments for eczema: network meta-analysis;Cochrane Database of Systematic Reviews;2024-08-06

2. New and Upcoming Topical Treatments for Atopic Dermatitis: A Review of the Literature;Journal of Clinical Medicine;2022-08-24

3. Phosphodiesterase‑4 inhibitors: a review of current developments (2013–2021);Expert Opinion on Therapeutic Patents;2022-01-17

4. Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis;Current Therapeutic Research;2022

5. Soft drugs for dermatological applications: recent trends;Drug Discovery Today;2019-12